ReviewLife (Basel, Switzerland)2025
A Review of Artificial Intelligence-Based Systems for Non-Invasive Glioblastoma Diagnosis.
Review in Life (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Integrating ex vivo platforms with AI to guide glioblastoma treatment.Journal of neuro-oncology · 2026Review
- Antibody therapies in glioblastoma: Overcoming micro-environmental barriers.Iranian journal of basic medical sciences · 2026Review
- Mapping knowledge landscapes and emerging trends in artificial intelligence in glioblastoma: A bibliometric analysis.Digital healthArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGlioblastoma multiforme (GBM) is an aggressive brain tumor with a poor prognosis. Traditional diagnosis relies on invasive biopsies, which pose surgical risks. Advances in artificial intelligence (AI) and machine learning (ML) have improved non-invasive GBM diagnosis using magnetic resonance imaging (MRI), offering potential advantages in accuracy and efficiency.
objectiveThis review aims to identify the methodologies and technologies employed in AI-based GBM diagnostics. It further evaluates the performance of AI models using standard metrics, highlighting both their strengths and limitations. METHODOLOGY: In accordance with the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines, a systematic review was conducted across major academic databases. A total of 104 articles were identified in the initial search, and 15 studies were selected for final analysis after applying inclusion and exclusion criteria. OUTCOMES: The included studies indicated that the signal T1-weighted imaging (T1WI) is the most frequently used MRI modality in AI-based GBM diagnostics. Multimodal approaches integrating T1WI with diffusion-weighted imaging (DWI) and apparent diffusion coefficient (ADC) have demonstrated improved classification performance. Additionally, AI models have shown potential in surpassing conventional diagnostic methods, enabling automated tumor classification and enhancing prognostic predictions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.